June 6, 2017
New data revealed an association between postmenopausal estrogen use and a reduced risk for hepatocellular carcinoma and increased overall survival time in women with HCC.
“In view of the notable male predominance of HCC, several investigators raised the question about the importance of sex hormones in HCC risk and prognosis. The liver expresses estrogen and androgen receptors, both of which may act as transcription factors and may regulate expression of several regulatory genes involved in several pathways including those associated with cell proliferation and immune response,” the researchers wrote. “This study demonstrates 50% reduction in HCC risk development among women who used [menopause hormone therapy].”